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Background: Breast cancer incidence within an area is usually proportional to the area’s income level. High-income
areas have shown the highest incidence rates and since 2003, negative trends. As for mortality, rates are often
higher in low-income regions. The purpose of this study was to analyze trends in incidence and mortality in a
capital city of a northeastern Brazilian state with an intermediate human development index.
Methods: Incidence data from the Population-Based Cancer Registry of Aracaju and mortality data from the Official
State Database for the period 1996–2006 were used. Incidence and mortality crude and age-standardized rates
were calculated. Time trends were obtained using the Joinpoint Regression Model.
Results: For the period studied, invasive breast cancer age-standardized incidence rates increased annually with an
annual percentage change (APC) of 2.9 (95% CI: 1.2-4.6). Significant increasing trends were observed in groups aged
45–54 years (APC: 3.9, 95% CI: 1.4 to 6.6), and 55–64 years (APC: 5.6, 95% CI: 1.8 to 9.6). Age-standardized mortality
rates did not show an increasing trend (APC: 3.0, (95% CI: -2.8 to9.1), except for the group aged 55–64 years
(APC: 11.3, 95% CI: 1.1 to 22.4).
Conclusions: In the study community, breast cancer showed increasing incidence among women in the peri- and
postmenopausal periods. However, mortality did not present increasing overall trends, except for among the group
aged 55–64 years. For better outcomes, screening policies should focus on the peri- and postmenopausal periods
of women’s lives to diagnose disease.
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In 2008, breast cancer was the most common female
neoplasm in both low- and high-income countries, and
accounted for 23% of all incident cases and 14% of all
female deaths worldwide. It presents a great burden on
women because it is the leading cause of cancer related
death among them worldwide [1,2]. In Brazil, cancer
incidence estimates for 2012 include a crude rate for
breast cancer of 52.50/100,000. For the State of Sergipe,
the crude rate has been estimated at 34.95/100,000 and
for the capital Aracaju, at 57.76/100,000 [3].* Correspondence: limaca@infonet.com.br
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reproduction in any medium, provided the orThe highest incidences of breast cancer are in
high-income countries of North America, Europe and
Australasia. High incidence also occurs in low- and
middle-income areas, where low fat ingestion has been
observed, calling attention to the multifactorial nature of
breast cancer development [4,5]. Conversely, for breast
cancer mortality, higher rates have been observed in
lower income areas, probably reflecting late diagnosis
and inadequate access to treatment facilities [6].
Disparities in breast cancer incidence and mortality
have been well discussed and linked to several causes.
Screening mammography, which has been performed
since the 1980s, has played an important role in early
cancer diagnosis. While screening has led to trends of
decreasing mortality, it has only done so in places
where screening has been systematic and thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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raphy [7]. Decreasing incidence trends have been
reported in high-income countries since 2003, follow-
ing the Women’s Health Initiative report that led to a
dramatic decline in hormone replacement therapy
(HRT) use [8,9]. However, the impact on mortality
needs to be verified.
It is the aim of the present study to analyze time
trends in breast cancer incidence and mortality in a
mid-income town of northeastern Brazil and offer means
to implement control policies to reduce mortality from
this common cancer.
Methods
Aracaju is the capital of the State of Sergipe, northeastern
Brazil, and is located at 10°54`40``S 37°04`18``W, has a
population of 571,149, predominantly urban, and a
Human Development Index (HDI) of 0.794 [10].
This was an ecological study of time trends that aimed
to describe changes in breast cancer incidence and mor-
tality in Aracaju. Data of all invasive breast cancer cases
were obtained from the Cancer Registry of Aracaju,
which has collected incident case data since 1996. A
database excluding in situ and non-melanoma skin cancer
was specially prepared for the study. The Cancer Registry
of Aracaju has actively collected cancer case data from
public and private sources, especially medical facilities
that provide cancer treatment. Some government data-
bases such as the information systems on hospital and
outpatient procedures, the information systems on breast
and cervical cancer, and the mortality system were also
used to identify cases and complete information of in-
cident cases. Mortality data were retrieved from the
Mortality Database of the State of Sergipe, which pro-
vided information for the Brazilian Mortality Database.
Mid-year female population data by year for the Munici-
pality of Aracaju were obtained from the official source,
DATASUS. Initially, five-year age groups were created,
then age groups (<45, 45–54, 55–64, and 65+ years) were
created to approximate premenopause, perimenopause,
the first ten years of the postmenopausal period, and
thereafter, respectively.
The Cancer Registry of Aracaju has been officially
integrated to the Brazilian National Cancer Institute
(INCA) and has followed the rules determined by the
International Agency for Research on Cancer (IARC).
For the period 1996 to 2006, all cases of invasive breast
cancer were included in the registry. Crude rates (CRs)
and age-standardized rates (ASRs), adjusted by the World
Population [11,12], were calculated using Cancer Registry
software [13]. Ninety-five percent confidence intervals
(95% CI) were calculated by the formula 95% CI =
R+/− (1.96xSE), where R was the annual rate and SE the
standard error. The standard error was calculated by theformula SE = R/√N, where R was the annual rate and
N the number of cases per year. The mortality/incidence
ratio was calculated using CRs to provide an indication
of the prognosis of breast cancer patients. The Joinpoint
Regression Program [14] was used to calculate time
trends in incidence and mortality with a model based on
the assumption of a minimal number of join points
where statistically significant changes in time trends
occur. It was a logarithmic linear model that added join
points, from 0 to 5, and calculated the difference up to a
statistically significant value, using the Monte Carlo Per-
mutation Test [15]. Thus, the Annual Percent Change
(APC) was calculated, and time trends in breast cancer
incidence and mortality were defined. Time trends for
the consecutive eleven-year series were calculated using
CRs, ASRs, and age-specific rates (age groups <45,
45–54, 55–64, and 65+ years) as the dependent varia-
bles; the year as the independent variable and the Input
Standard Error of Dependent Variable was chosen with
appropriate standard error calculations (formula men-
tioned above).
Results
During the study period, 1,264 cases of invasive breast
cancer and 336 breast cancer deaths were identified.
Age-specific, crude and age-standardized breast cancer
incidence (Table 1) and mortality (Table 2) rates are pre-
sented. Some fluctuation was observed in the annual
rates, but no special reason could be found for it. Crude
incidence rates varied from 38.2/100,000 (95% CI: 30.2
to 46.2) and 32.9/100,000 (95% CI: 25.5 to 40.2) in the
early years (1996 and 1997) to 54.3/100,000 (95% CI:
45.4 to 63.1) and 52.4/100,000 (95% CI: 43.8 to 61.1) in
the later years of the series (2005 and 2006). Compared
with the <45 age group, higher rates were observed in the
perimenopausal period, and rates were highest in the post-
menopausal periods of women’s lives. Age-standardized
incidence rates varied from 49.6/100,000 (95% CI: 39.2 to
60.0) and 42.5/100,000 (95% CI: 33.0 to 52.1) in the early
years to 64.0/100,000 (95% CI: 53.5 to 74.4) and 60.8/
100,000 (95% CI: 50.8 to 70.8) in the later years of the
series. Mortality rates also fluctuated over the years. CRs
varied from 9.2/100,000 (95% CI: 5.2 to 13.3) in 1996 and
8.6/100,000 (95% CI: 4.9 to 12.4) in 1997 to 16.2/100,000
(95% CI: 11.4 to 21.0) in 2005 and 12.6/100,000 (95% CI:
8.4 to 16.9) in 2006. Age-specific mortality rates were
higher in the postmenopausal period. Age-standardized
mortality rates were 11.4/100,000 (95% CI: 6.5 to 16.2) in
1996, climbed to 21.4/100,000 (95% CI: 15.3 to 27.6) in
2001, then dropped to 14.7/100,000 (95% CI: 9.8 to 19.6)
in 2006. The mean mortality-to-incidence ratio for the
time series was 0.27.
As seen in Table 3, trends in breast cancer incidence
and mortality were calculated using Joinpoint analyses
Table 1 Breast cancer incidence, with age-specific case
counts (N), crude rates (CR) and age-standardized rates
(ASR), Aracaju, Sergipe, Brazil, 1996–2006
Year Age N CR (95% CI) ASR (95% CI)
1996 All 87 38.2 (30.2-46.2) 49.6 (39.2-60.0)
<45 21 26.2 (15.0-37.4)
45–54 21 134.8 (77.1-192.4)
55–64 17 150.5 (78.9-222.0)
65+ 28 258.4 (162.7-354.1)
1997 All 76 32.9 (25.5-40.2) 42.5 (33.0-52.1)
<45 23 29.6 (17.5-41.7)
45–54 20 103.1 (57.9-148.4)
55–64 11 98.4 (40.3-156.6)
65+ 22 156.3 (91.0-221.6)
1998 All 90 38.4 (30.5-46.4) 50.5 (40.1-61.0)
<45 19 23.3 (12.8-33.8)
45–54 23 150.1 (88.7-211.3)
55–64 20 178.0 (100.0-256.0)
65+ 28 270.5 (170.3-370.6)
1999 All 104 43.9 (35.4-52.3) 55.8 (45.1-66.5)
<45 24 29.5 (17.7-41.3)
45–54 28 162.0 (102.0-221.9)
55–64 20 177.5 (99.7-255.3)
65+ 32 307.4 (200.9-413.9)
2000 All 115 46.8 (38.3-55.4) 53.6 (43.8-63.4)
<45 29 33.3 (21.2-45.4)
45–54 40 156.8 (108.2-205.3)
55–64 17 133.0 (69.8-196.3)
65+ 28 211.4 (133.1-289.7)
Unknown 1
2001 All 118 47.3 (38.8-55.9) 56.5 (46.3-66.7)
<45 24 25.7 (15.4-35.9)
45–54 26 175.2 (107.9-242.6)
55–64 30 231.9 (148.9-314.9)
65+ 37 250.8 (170.0-331.7)
Unknown 1
2002 All 141 55.9 (46.7-65.1) 63.5 (53.0-74.0)
<45 38 42.1 (28.7-55.5)
45–54 47 186.2 (133.0-239.5)
55–64 23 174.5 (103.2-245.8)
65+ 32 230.8 (150.8-310.8)
Unknown 1
2003 All 112 43.9 (35.7-52.0) 52.0 (42.4-61.7)
<45 26 30.4 (18.7-42.1)
45–54 29 152.8 (97.2-208.5)
55–64 26 181.9 (112.0-251.8)
65+ 31 199.9 (129.5-270.3)
Table 1 Breast cancer incidence, with age-specific case
counts (N), crude rates (CR) and age-standardized rates
(ASR), Aracaju, Sergipe, Brazil, 1996–2006 (Continued)
2004 All 136 52.6 (43.8-61.5) 61.5 (51.2-71.8)
<45 32 34.5 (22.5-46.5)
45–54 31 181.8 (117.8-245.8)
55–64 32 232.4 (151.9-312.9)
65+ 41 291.2 (202.0-380-3)
2005 All 144 54.3 (45.4-63.1) 64.0 (53.5-74.4)
<45 26 28.3 (17.4-39.2)
45–54 35 181.0 (121.0-241.0)
55–64 32 219.2 (143.2-295.1)
65+ 51 363.5 (263.7-463.3)
2006 All 141 52.4 (43.8-61.1) 60.8 (50.8-70.8)
<45 29 30.4 (19.3-41.4)
45–54 32 188.0 (122.9-253.1)
55–64 35 243.7 (162.9-324.4)
65+ 44 337.4 (237.7-437.1)
Unknown 1
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all age groups, there was an increasing trend, with an
ASR-APC of 2.9 (95% CI: 1.1 to 4.6) and a CR-APC of
4.1 (95% CI: 2.0 to 6.3). In the groups aged 45–54 and
55–64 years, the APC was 3.9 (95% CI: 1.4 to 6.6) and
5.6 (95% CI: 1.8 to 9.6), respectively. For mortality, the
overall trend was not statistically significant, with an
ASR-APC of 3.0 (95% CI: -2.8 to 9.1) and a CR-APC of
3.9 (95% CI: -2.2 to 10.3). The only significant mortality
trend was observed in the group aged 55–64 years, with
an APC of 11.3 (95% CI: 1.1 to 22.4). The incidence and
mortality trend curves are displayed in Figure 1.
Discussion
Breast cancer incidence is higher in high-income coun-
tries, because of its links with several risk factors [16]
and the presence of systematic screening policies [17].
However, a decreasing trend has been observed since
2003 due to the decreasing use of HRT [18]. Lower in-
cidence rates in low-income countries probably reflect
international variation in hormonal factors and accessi-
bility to early detection facilities [19,20].
Screening practices in Brazil were outlined by the
Brazilian National Cancer Institute [21] and have been
followed by the states and municipalities. Screening
guidelines include biannual mammography for women
aged 50 to 69 years, and have been made public through
occasional media campaigns.
In the study period, increasing CRs and ASRs were
observed (Table 1 and Figure 1). In 1996, the ASR was
Table 2 Breast cancer mortality, with age-specific case
counts (N), crude rates (CR) and age-standardized rates
(ASR), Aracaju, Sergipe, Brazil, 1996–2006
Year Age N CR (95% CI) ASR (95% CI)
1996 All 20 9.2 (5.2-13.3) 11.4 (6.5-16.2)
<45 8 9.9 (3.0-16.7)
45–54 4 25.5 (0.5-50.4)
55–64 2 18.6 (−7.2-44.5)
65+ 6 57.7 (11.5-103.9)
1997 All 20 8.6 (4.9-12.4) 11.4 (6.4-16.4)
<45 4 5.0 (0.1-9.9)
45–54 1 6.3 (−6.0-18.6)
55–64 4 35.0 (0.7-69.3)
65+ 11 108.5 (44.4-172.6)
1998 All 24 10.2 (6.1-14.3) 13.6 (8.1-19.0)
<45 4 5.0 (0.1-10.0)
45–54 7 38.6 (10.0-67.2)
55–64 5 48.0 (5.9-90.1)
65+ 8 96.2 (29.5-162.9)
1999 All 28 11.8 (7.4-16.2) 14.5 (9.1-19.8)
<45 6 7.8 (1.6-14.1)
45–54 10 51.8 (19.7-84.0)
55–64 2 17.9 (−6.9-42.8)
65+ 10 106.5 (40.5-172.5)
2000 All 31 12.6 (8.2-17.1) 13.8 (9.0-18.7)
<45 10 11.3 (4.3-18.3)
45–54 12 52.4 (22.7-82.0)
55–64 3 20.7 (−2.7-44.2)
65+ 6 46.2 (9.2-83.2)
Unknown
2001 All 47 18.9 (13.5-24.2) 21.4 (15.3-27.6)
<45 7 7.3 (1.9-12.8)
45–54 17 78.5 (41.2-115.8)
55–64 8 60.6 (18.6-102.6)
65+ 15 135.0 (66.7-203.4)
Unknown
2002 All 23 9.1 (5.4-12.8) 10.2 (6.0-14.3)
<45 5 5.8 (0.7-10.9)
45–54 7 29.8 (7.7-51.9)
55–64 4 31.5 (0.6-62.3)
65+ 7 67.0 (17.4-116.7)
Unknown
2003 All 41 16.1 (11.1-21.0) 20.1 (13.9-26.2)
<45 7 7.5 (1.9-13.0)
45–54 9 40.2 (13.9-66.5)
55–64 13 98.4 (44.9-151.9)
65+ 12 83.9 (36.4-131.4)
Table 2 Breast cancer mortality, with age-specific case
counts (N), crude rates (CR) and age-standardized rates
(ASR), Aracaju, Sergipe, Brazil, 1996–2006 (Continued)
2004 All 25 9.7 (5.9-13.5) 11.5 (7.0-15.9)
<45 5 5.4 (0.7-10.2)
45–54 2 8.3 (−3.2-19.9)
55–64 9 62.1 (21.5-102.7)
65+ 9 64.1 (22.2-105.9)
2005 All 43 16.2 (11.4-21.0) 18.8 (13.2-24.5)
<45 8 9.0 (2.8-15.3)
45–54 9 35.6 (12.3-58.8)
55–64 11 74.7 (30.6-118.9)
65+ 15 106.9 (52.6-160.5)
2006 All 34 12.6 (8.4-16.9) 14.7 (9.8-19.6)
<45 9 10.0 (3.5-16.6)
45–54 6 24.4 (4.9-44.0)
55–64 9 63.9 (22.2-105.7)
65+ 10 79.5 (30.2-128.8)
Unknown
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years, it had some fluctuation before becoming stable
with rates higher than 60.0/100,000 in the last years of
the series. Rates as high as these have been observed in
other mid-income countries [22] and could be justified
in an area with an intermediate HDI such as Aracaju.
Increasing trends (Table 3) were observed in the
study, with an ASR-APC of 2.9 (95% CI: 1.1 to 4.6) and a
CR-APC of 4.1 (95% CI: 2.0 to 6.3). Incidence rates
were higher in peri- and postmenopausal women, with
increasing trends in the groups aged 45–54 (APC: 3.9,
95% CI: 1.4 to 6.6) and 55–64 (APC: 5.6, 95% CI: 1.8 to
9.6) years. In the study community, formal screening
invitations are not conducted. Rather, mammography isTable 3 Joinpoint analyses of breast cancer incidence and
mortality with the estimated annual percent change
(APC) for age-specific groups, crude rates (CR), age-
standardized rates (ASR), and 95% confidence intervals
(CI), Aracaju, Sergipe, Brazil, 1996–2006
Incidence Mortality
Age
groups
Join
points
APC
(95% CI)
Join
points
APC
(95% CI)
All (ASR) 0 2.9* (1.1-4.6) 0 3.0 (−2,8-9.1)
All (CR) 0 4.1* (2.0-6.3) 0 3.9 (−2.2-10.3)
<45 0 1.8 (−1.9-5.6) 0 0.8 (−5.0-6.9)
45-54 0 3.9* (1.4-6.6) 0 −3.8 (−16.2-10.5)
55-64 0 5.6* (1.8-9.6) 0 11.3* (1.1-22.4)
65+ 0 4.1 (−0.5-8.9) 0 −0.4 (−7.2-6.9)
*Significant APC.
Figure 1 (See legend on next page.)
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Figure 1 Crude (Inc CR; 95% CI: 2.0 to 6.3) and age-standardized (Inc ASR; 95% CI: 1.1 to 4.6) breast cancer incidence rates and crude
(Mor CR; 95% CI: -2.2 to 10.3) and age-standardized (Mor ASR; 95% CI: -2.8 to 9.1) mortality rates, Aracaju, Sergipe, Brazil, 1996–2006).
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practitioner because of other health problems, or even to
request screening. This might somehow reflect the in-
creasing trends in these age groups. Screening has been
more consistently available since the early 1990s, when
breast specialists began practicing in this community. In
addition, first generation high-resolution breast imaging
has also become available. Screening guidelines were
established in 2004 on a biannual basis for women aged
50 to 69 years. The number of women in different age
groups actually being screened is unknown. Furthermore,
the role of HRT could not be established and might be
worthy of future research.
Mortality rates are higher in high-income countries,
but with decreasing trends, with a median ASR of 15.3/
100,000 [22,23]. In the United States, for instance, mor-
tality rates standardized by the American population va-
ried from 21.5/100,000 to 28.0/100,000, depending on
the state, but have also presented decreasing trends [24].
Low-income areas have shown a median ASR of 10.0/
100,000, but with increasing trends [22,23]. Possible
explanations for this are the low incidence rates observed
in those areas, and the lack of risk factors typically seen
in high-income countries. Regarding increasing trends,
inefficacy to detect less advanced tumors and lower ac-
cessibility to treatment facilities were suggested [19,20].
In our study, crude and age-standardized mortality
rates fluctuated throughout the years. A mean age-
standardized mortality rate of 14.7/100,000 was observed
in the 1996–2006 period. No significant trends were
observed, with an ASR-APC of 3.0/100,000 (95% CI: -2.8
to 9.1) and CR-APC of 3.9 (95% CI: -2.2 to 10.3). How-
ever, there has been an increasing trend for the group
aged 55–64 years, with an APC of 11.3 (95% CI: 1.1 to
22.4), probably reflecting the trend of increasing inci-
dence in the peri- and postmenopausal periods. Actual
cause of death has been a matter of discussion, because it
has not always been adequately interpreted. In our study,
breast cancer death was considered when it was certified
as the underlying or contributing cause.
The mortality-to-incidence ratio has been advocated
as a proxy for cancer survival, taken by 1-(M/R) [25].
Mortality-to-incidence ratios around 0.24 have been
observed in high-income countries, compared with 0.40
in less developed and 0.60 in low-income areas such as
Africa [26]. In the present study, a mean ratio of 0.27,
which is similar to those of high-income areas, is rather
satisfactory, but might be confirmed more accurately
by survival studies.It has been suggested that systematic screening, to-
gether with implementing better treatment facilities is
the key to decreasing mortality rates [27,28], but scree-
ning is sometimes contested because of the high cost of
establishing mammography equipment, the low yield of
biopsies, the lead time bias, and the diagnosis of lesions
that would never become invasive [17].
Limitations
The Population-Based Cancer Registry of Aracaju has
registered incident cancer cases in the State of Sergipe
and has then selected cases from the area of Aracaju.
This has resulted in a delay to close the annual database
and case ascertainment has been more tedious. There
have been some cases for whom place of residence could
not be determined. Even after examining all sources and
databases, a few cases still had to be excluded. The data
were retrieved from several different sources of informa-
tion, and some cases could be found in more than one
information source; therefore, extra care had to be exer-
ted to avoid duplication. Mortality rates were calculated
from death records of the Official State Mortality Data-
base. The cause of death has been criticized as being in-
adequately precise, mainly in developing areas, which
jeopardizes our conclusions. However, official data were
used and all possible effort was put into improving the
quality of information.
Conclusions
The present study demonstrated that breast cancer inci-
dence has been increasing over time. This increasing
trend may continue more steadily with the aging of the
still-young female population and if more systematic
screening policies are implemented. Mortality trends
were not observed to be increasing, except for the group
aged 55–64 years. Control policies should aim to more
accurately screen women in the peri- and postmenopausal
periods to diagnose smaller tumors that could have better
outcomes. It was not the aim of this study to analyze
the causes of the increase in incidence and the impact
on mortality rates. Additional research needs to be con-
ducted to identify factors that could be related to this
crescent trend to better design strategies to minimize
the impact on mortality.
N, Number of cases; se, standard error.
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